Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 396,100 shares, an increase of 278.0% from the October 15th total of 104,800 shares. Based on an average trading volume of 252,700 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.9% of the company’s stock are short sold.
Wall Street Analysts Forecast Growth
Separately, Raymond James decreased their price target on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research note on Friday, November 8th.
Institutional Inflows and Outflows
Xilio Therapeutics Stock Performance
Shares of NASDAQ XLO opened at $1.08 on Wednesday. The stock has a market cap of $47.47 million, a price-to-earnings ratio of -0.62 and a beta of -0.24. Xilio Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $1.93. The firm’s 50-day simple moving average is $0.89 and its 200 day simple moving average is $0.95.
About Xilio Therapeutics
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.
Recommended Stories
- Five stocks we like better than Xilio Therapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Insider Trades May Not Tell You What You Think
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.